Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;caac.21660.
O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(S3):20–9. https://doi.org/10.1634/theoncologist.10-90003-20.
Mamounas EP, Mitchell MP, Woodward WA. Molecular predictive and prognostic markers in locoregional management. J Clin Oncol. 2020;38(20):2310–20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol. 2014;2014:469251.
Article
PubMed
PubMed Central
CAS
Google Scholar
Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, et al. Effects of estrogen receptor and human epidermal growth factor receptor-2 levels on the efficacy of trastuzumab: a secondary analysis of the HERA trial. JAMA Oncol. 2016;2(8):1040–7.
Article
PubMed
Google Scholar
Lutgendorf SK, Andersen BL. Biobehavioral approaches to cancer progression and survival: mechanisms and interventions. Am Psychol. 2015;70(2):186–97.
Article
PubMed
PubMed Central
Google Scholar
Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010;70(18):7042–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Obradović MMS, Hamelin B, Manevski N, Couto JP, Sethi A, Coissieux MM, et al. Glucocorticoids promote breast cancer metastasis. Nature. 2019;567:540 (Nature Publishing Group).
Article
PubMed
CAS
Google Scholar
Pan D, Kocherginsky M, Conzen SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 2011;71(20):6360–70.
Article
CAS
PubMed
PubMed Central
Google Scholar
West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, et al. Discovery of a glucocorticoid receptor (gr) activity signature using selective gr antagonis in er-negative breast cancer. Clin Cancer Res. 2018;24(14):3433–46.
Article
CAS
PubMed
PubMed Central
Google Scholar
Karmakar S, Jin Y, Nagaich AK. Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) α and activator protein 1 (AP1) in dexamethasone-mediated interference of ERα activity. J Biol Chem. 2013;288(33):24020–34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Koker SC, Jahja E, Shehwana H, Keskus AG, Konu O. Cholinergic receptor nicotinic alpha 5 (CHRNA5) RNAi is associated with cell cycle inhibition, apoptosis DNA damage response and drug sensitivity in Breast cancer. PLoS One. 2018;13(12):e0208982.
Article
CAS
Google Scholar
Salem AR, Martínez Pulido P, Sanchez F, Sanchez Y, Español AJ, Sales ME. Effect of low dose metronomic therapy on MCF-7 tumor cells growth and angiogenesis. Role of muscarinic acetylcholine receptors. Int Immunopharmacol. 2020;84:106514.
Article
CAS
PubMed
Google Scholar
Sun Z, Bao J, Zhangsun M, Dong S, Zhangsun D, Luo S. ΑO-conotoxin GexIVa inhibits the growth of breast cancer cells via interaction with α9 nicotine acetylcholine receptors. Mar Drugs. 2020;18(4):195.
Article
CAS
PubMed Central
Google Scholar
Sarkar C, Chakroborty D, Chowdhury UR, Dasgupta PS, Basu S. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res. 2008;14(8):2502–10.
Article
CAS
PubMed
Google Scholar
Minami K, Liu S, Liu Y, Chen A, Wan Q, Na S, et al. Inhibitory effects of dopamine receptor D 1 agonist on mammary tumor and bone metastasis. Sci Rep. 2017;7:45686.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pai VP, Marshall AM, Hernandez LL, Buckley AR, Horseman ND. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res. 2009;11(6):R81.
Article
PubMed
PubMed Central
CAS
Google Scholar
Gwynne WD, Hallett RM, Girgis-Gabardo A, Bojovic B, Dvorkin-Gheva A, Aarts C, et al. Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts. Oncotarget. 2017;8(19):32101–16.
Article
PubMed
PubMed Central
Google Scholar
Gao QG, Li ZM, Wu KQ. Partial least squares based analysis of pathways in recurrent breast cancer. Eur Rev Med Pharmacol Sci. 2013;17(16):2159–65.
PubMed
Google Scholar
Lu D, Carlsson J, Penney KL, Davidsson S, Andersson S-O, Mucci LA, et al. Expression and genetic variation in neuroendocrine signaling pathways in lethal and nonlethal prostate cancer among men diagnosed with localized disease. Cancer Epidemiol Biomarkers Prev. 2017;26(12):1781–7.
Article
CAS
PubMed
Google Scholar
Lu D, Sinnott JA, Valdimarsdóttir U, Fang F, Gerke T, Tyekucheva S, et al. Stress-related signaling pathways in lethal and nonlethal prostate cancer. Clin Cancer Res. 2016;22(3):765–72.
Article
CAS
PubMed
Google Scholar
Xie Y, Valdimarsdóttir UA, Wang C, Zhong X, Gou Q, Zheng H, et al. Public health insurance and cancer-specific mortality risk among patients with breast cancer: a prospective cohort study in China. Int J Cancer. 2021;148(1):28–37.
Article
CAS
PubMed
Google Scholar
The Cancer Genome Atlas Program - National Cancer Institute. https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga.
Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An Integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400-416.e11.
Article
CAS
PubMed
PubMed Central
Google Scholar
Salim A, Ma X, Fall K, Andrén O, Reilly M. Analysis of incidence and prognosis from “extreme” case-control designs. Stat Med. 2014;33(30):5388–98.
Article
PubMed
Google Scholar
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, et al. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol. 2015;26(5):873–9.
Article
CAS
PubMed
Google Scholar
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754–60.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 2019;37(8):907–15.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wu H-X, Wang Z-X, Zhao Q, Chen D-L, He M-M, Yang L-P, et al. Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. Ann Transl Med. 2019;7(22):640–640.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ding H, Zhao J, Zhang Y, Wang G, Cai S, Qiu F. Tumor mutational burden and prognosis across pan-cancers. Ann Oncol. 2018;29(viii16):7.
Google Scholar
Barroso-Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido-Castro AC, et al. Tumor mutational burden and pten alterations as molecular correlates of response to pd-1/l1 blockade in metastatic triple-negative breast cancer. Clin Cancer Res. 2020;26(11):2565–72.
Article
CAS
PubMed
PubMed Central
Google Scholar
Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 2010;11(3):R25.
Article
PubMed
PubMed Central
CAS
Google Scholar
Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882.
Article
CAS
PubMed
PubMed Central
Google Scholar
Goeman JJ, Van de Geer S, De Kort F, van Houwellingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics. 2004;20(1):93–9.
Article
CAS
PubMed
Google Scholar
He L, Yuan L, Sun Y, Wang P, Zhang H, Feng X, et al. Glucocorticoid receptor signaling activates TEAD4 to promote breast cancer progression. Cancer Res. 2019;79(17):4399–411.
Article
CAS
PubMed
Google Scholar
Klimczak M, Biecek P, Zylicz A, Zylicz M. Heat shock proteins create a signature to predict the clinical outcome in breast cancer. Sci Reports. 2019;9(1):1–15.
CAS
Google Scholar
Fan Y, Mu J, Huang M, Imani S, Wang Y, Lin S, et al. Epigenetic identification of ADCY4 as a biomarker for breast cancer: an integrated analysis of adenylate cyclases. Epigenomics. 2019;11(14):1561–79.
Article
CAS
PubMed
Google Scholar
Mei J, Wang T, Zhao S, Zhang Y. Osthole inhibits breast cancer progression through upregulating tumor suppressor GNG7. J Oncol. 2021;2021:6610511.
PubMed
PubMed Central
Google Scholar
Liu JY, Dai YB, Li X, Cao K, Xie D, Tong ZT, et al. Solute carrier family 12 member 5 promotes tumor invasion/metastasis of bladder urothelial carcinoma by enhancing NF-κB/MMP-7 signaling pathway. Cell Death Dis. 2017;8(3):e2691–e2691.
Article
CAS
PubMed
PubMed Central
Google Scholar
Xu L, Li X, Cai M, Chen J, Li X, Wu WKK, et al. Original article: Increased expression of Solute carrier family 12 member 5 via gene amplification contributes to tumour progression and metastasis and associates with poor survival in colorectal cancer. Gut. 2016;65(4):635.
Article
CAS
PubMed
Google Scholar
Yang G-P, He W-P, Tan J-F, Yang Z-X, Fan R-R, Ma N-F, et al. Overexpression of SLC12A5 is associated with tumor progression and poor survival in ovarian carcinoma. Int J Gynecol Cancer. 2019;29:1280–4.
Article
PubMed
Google Scholar
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.
Article
PubMed
Google Scholar
Győrffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Hoffman JA, Papas BN, Trotter KW, Archer TK. Single-cell RNA sequencing reveals a heterogeneous response to Glucocorticoids in breast cancer cells. Commun Biol. 2020;3(1):126.
Article
PubMed
PubMed Central
Google Scholar
Cassileth PA, Lusk EJ, Torri S, DiNubile N, Gerson SL. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med. 1983;143(7):1347–9.
Article
CAS
PubMed
Google Scholar
Martin JD, Panagi M, Wang C, Khan TT, Martin MR, Voutouri C, et al. Dexamethasone increases cisplatin-loaded nanocarrier delivery and efficacy in metastatic breast cancer by normalizing the tumor microenvironment. ACS Nano. 2019;13(6):6396–408.
Article
CAS
PubMed
Google Scholar
Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92:994–1000.
Article
CAS
PubMed
Google Scholar
Zeitzer JM, Nouriani B, Rissling MB, Sledge GW, Kaplan KA, Aasly L, et al. Aberrant nocturnal cortisol and disease progression in women with breast cancer. Breast Cancer Res Treat. 2016;158(1):43.
Article
CAS
PubMed
PubMed Central
Google Scholar
Leoncikas V, Wu H, Ward LT, Kierzek AM, Plant NJ. Generation of 2,000 breast cancer metabolic landscapes reveals a poor prognosis group with active serotonin production. Sci Rep. 2016;6:19771.
Article
CAS
PubMed
PubMed Central
Google Scholar